6533b7d1fe1ef96bd125c321
RESEARCH PRODUCT
Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas.
Claudio TripodoS. CiavarellaStefano PileriFederica MelleMaria Carmela VeglianteStefano FioriSaveria MazzaraGiovanna MottaValentina TabanelliEnrico DerenziniEnrico Derenzinisubject
0301 basic medicineOncologymedicine.medical_specialtydiagnosisdiffuse large B-cell lymphomaReviewSettore MED/08 - Anatomia Patologica03 medical and health sciences0302 clinical medicineInternal medicineDaily practicemedicineTumor MicroenvironmentHumanslcsh:QH301-705.5B celltherapybusiness.industryGene Expression ProfilingNot Otherwise SpecifiedHigh-Throughput Nucleotide SequencingGeneral Medicinemedicine.diseaseMicroarray AnalysisPrognosisLymphomaGene expression profilingdiagnosi030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)Lymphoid malignancyclassification030220 oncology & carcinogenesisnext-generation sequencingLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomaprognosidescription
Diffuse large B-cell lymphoma (DLBCL) is the commonest form of lymphoid malignancy, with a prevalence of about 40% worldwide. Its classification encompasses a common form, also termed as “not otherwise specified” (NOS), and a series of variants, which are rare and at least in part related to viral agents. Over the last two decades, DLBCL-NOS, which accounts for more than 80% of the neoplasms included in the DLBCL chapter, has been the object of an increasing number of molecular studies which have led to the identification of prognostic/predictive factors that are increasingly entering daily practice. In this review, the main achievements obtained by gene expression profiling (with respect to both neoplastic cells and the microenvironment) and next-generation sequencing will be discussed and compared. Only the amalgamation of molecular attributes will lead to the achievement of the long-term goal of using tailored therapies and possibly chemotherapy-free protocols capable of curing most (if not all) patients with minimal or no toxic effects.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-12 | Cells |